Literature DB >> 12121783

Hydrolytically active Eu(III) and Ce(IV) EF-hand peptides.

Mallena Sirish1, Sonya J Franklin.   

Abstract

A chimeric peptide (P4) has been designed to incorporate an EF-hand metal-binding loop into the context of the helix-turn-helix DNA binding motif of the engrailed homeodomain. This construct binds lanthanides, and in the presence of these metals, promotes the cleavage of supercoiled DNA and model phosphate esters (bisnitrophenyl phosphate). P4 binds lanthanides with moderate affinities (Eu(III), log K(a)=4.85; and Ce(IV), log K(a)=5.23). The structure of P4 is enhanced by metal binding, but the increase in secondary structure observed by CD is small, and suggests the metallopeptide is also quite flexible. Despite this flexibility, the efficient cleavage of DNA at low concentrations is dependent on the metallopeptide, and not on peptide or metal alone. This enhanced reactivity suggests the designed DNA-binding EF-hand peptides deliver the metal to the DNA for catalysis, even without rigid secondary structure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12121783     DOI: 10.1016/s0162-0134(02)00408-7

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  3 in total

1.  Sequence preference in DNA binding: de novo designed helix-turn-helix metallopeptides recognize a family of DNA target sites.

Authors:  Siu Wah Wong-Deyrup; Youngbae Kim; Sonya J Franklin
Journal:  J Biol Inorg Chem       Date:  2005-11-15       Impact factor: 3.358

2.  Ca 2+-induced self-assembly in designed peptides with optimally spaced gamma-carboxyglutamic acid residues.

Authors:  Qiuyun Dai; Mingxin Dong; Zhuguo Liu; Mary Prorok; Francis J Castellino
Journal:  J Inorg Biochem       Date:  2010-10-08       Impact factor: 4.155

3.  Lanthanide-binding helix-turn-helix peptides: solution structure of a designed metallonuclease.

Authors:  Joel T Welch; William R Kearney; Sonya J Franklin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.